Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
China Pharmacy ; (12): 2129-2132, 2022.
Article in Chinese | WPRIM | ID: wpr-941455

ABSTRACT

OBJECTIVE To mine the risk sig nals o f iodine contrast media from spontaneous reporting system. METHODS Reporting odds ratio ,proportional reporting ratio ,Medicines and Healthcare Products Regulatory Agency and Bayesian confidence propagation neural network were used to mine risk signals of 5 iodine contrast media (iopamidol,iohexol,iopromide,ioversol, iodixanol). RESULTS 1 164(2 446 case times )adverse drug reaction of iodine contrast media were included ,a total of 14 risk signals involving systems/organs such as respiratory system (3,2,4,3,2 for the above 5 iodine contrast media )and immune system and 32 specific adverse drug reaction signals including anaphylactic shock ,rash and flushing (11,7,7,3,4 for the above 5 iodine contrast media )were found in 5 iodine contrast media. CONCLUSIONS The risk signals of 5 iodine contrast media verify that there is a certain correlation between these drugs and above adverse drug reactions. It is suggested that before using iodine contrast media in clinic ,it is necessary to pay attention to whether the patient has a history of tumor and combined medication ,evaluate the patient’s renal function ,and give preventive measures such as hydration in advance. When using iodine contrast media ,it is necessary to pay attention to the temperature ,dose and injection rate. And medical staff need to follow up the patient ’s situation in time after using iodine contrast media to avoiding the impact of delayed adverse reactions.

2.
China Pharmacy ; (12): 1650-1653, 2020.
Article in Chinese | WPRIM | ID: wpr-822635

ABSTRACT

OBJECTIVE:To investigate th e cognition ,attitude and behavior of part of drug practitioners in Shenzhen on compensation of adverse drug reaction (ADR)injury,and to provide relevant reference for the establishment of ADR injury compensation system. METHODS :Taking marketing authorization holder (MAH),staff of medical institutions at the second level or above and drug regulatory authorities in the relevant meeting held in Shenzhen in 2018 as objects ,on-the-spot anonymous investigation of “questionnaire star ”was used to collect and analyze the cognition ,attitude(including attitude towards ADR compensation and ADR compensation system )and behavior of the above-mentioned personnel to ADR compensation. The relevant suggestion was put forward. RESULTS & CONCLUSIONS :A total of 172 questionnaires were collected (all being valid ). In term of cognition ,the respondents generally had high awareness of ADR (response rate of ADR concept was 82.0%). In term of attitude to ADR injury compensation ,100 respondents(58.1%)believed that ADR after medication should be compensated ,and 147 respondents(85.5%)believed that compensation should be made for serious and fatal adverse reactions. In term of attitude to ADR injury compensation system ,respondents thought that ADR damage compensation funds be undertaken by MAH for 131 case times (76.2%). As for the difficulties in the implementation of ADR compensation ,it was considered that the evaluation of the correlation between adverse reactions and drugs led to the difficulties in the implementation of ADR compensation (143 case times , 83.1%);most respondents thought that the first thing to do in the implementation of ADR compensation system was to implement laws and regulations (145 case times ,84.3%). In term of behavior ,104 respondents(60.5%)had processed costs due to ADR , most of whom chose self-resolved (85 cases,81.7%);112 respondents (65.1%) chose to inform medical personnels or pharmacies directly. It is suggested that the relevant departments in Shenzhen should explore and establish ADR injury compensation mechanism in Shenzhen by establishing a public oriented platform and mechanism for ADR science popularization (setting up relevant departments ,supervising the public propaganda of news media ,expanding the public propaganda to the commu nity),exploring and establishing ADR injury compensation mechanism (setting up a special legislative pilot of ADR injury regulations ,setting up ADR injury appraisal committee ),and increasing the investment in ADR testing (fully using of “Internet+”Big Data ,allocating special funds ).

3.
Chinese Journal of Epidemiology ; (12): 825-828, 2015.
Article in Chinese | WPRIM | ID: wpr-302070

ABSTRACT

Objective To investigate the infection status of Mycoplasma pirum among male HIV/AIDS patients in Jiangsu and analyze the risk factors.The genome sequencing of Mycoplasma pirum was completed for the first time.Methods Male HIV infected individuals and AIDS patients confirmed in Jiangsu province were enrolled for 4 repeated cross-sectional studies by means of detecting the first flow urine sample and venous blood sample collected and questionnaire survey after informed consent.Genome sequencing was conducted for Mycoplasma pirum by using Illumina Hiseq 2000 sequencing platform.Results A total of 1 541 HIV/AIDS patients were surveyed in this study.The infection rates of Mycoplasma pirurm was 15.4%.The patients who received no HAART had higher risk to be infected with Mycoplasma pirum (OR=1.344,95%CI:1.008-1.792).Otherwise,high CD4+T counts was a protective factor for Mycoplasma pirum infection (OR=0.600,95%CI:0.444-0.810).Based on the sequencing result,the genome size of Mycoplasma pirum was 850 704 bp,the GC content was 24.21% the genome contained 708 genes,the total length of genes was 734 085 bp,the average length was 1 037 bp,accounting for 86.29% of genome.Conclusion More attention should be paid to the high infection rate of Mycoplasma pirum among male HIV/AIDS patients in the future AIDS prevention and control.The first genome sequencing of standard Mycoplasma pirum strain was completed in this study (registering Serial number:AZHZ00000001),which can provide evidence for the further research of gene function and pathogenic mechanism of Mycoplasma pirum.

SELECTION OF CITATIONS
SEARCH DETAIL